JP2022527542A5 - - Google Patents
Info
- Publication number
- JP2022527542A5 JP2022527542A5 JP2021558985A JP2021558985A JP2022527542A5 JP 2022527542 A5 JP2022527542 A5 JP 2022527542A5 JP 2021558985 A JP2021558985 A JP 2021558985A JP 2021558985 A JP2021558985 A JP 2021558985A JP 2022527542 A5 JP2022527542 A5 JP 2022527542A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- ifn
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024152418A JP2025000638A (ja) | 2019-04-04 | 2024-09-04 | 抗IFN-α/ω抗体の投与方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962829317P | 2019-04-04 | 2019-04-04 | |
| US62/829,317 | 2019-04-04 | ||
| PCT/IB2020/053221 WO2020202106A1 (en) | 2019-04-04 | 2020-04-03 | Method of administration of an anti-ifn-alpha/-omega antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152418A Division JP2025000638A (ja) | 2019-04-04 | 2024-09-04 | 抗IFN-α/ω抗体の投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527542A JP2022527542A (ja) | 2022-06-02 |
| JP2022527542A5 true JP2022527542A5 (cg-RX-API-DMAC7.html) | 2023-03-27 |
Family
ID=72662887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021558985A Pending JP2022527542A (ja) | 2019-04-04 | 2020-04-03 | 抗IFN-α/ω抗体の投与方法 |
| JP2024152418A Pending JP2025000638A (ja) | 2019-04-04 | 2024-09-04 | 抗IFN-α/ω抗体の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024152418A Pending JP2025000638A (ja) | 2019-04-04 | 2024-09-04 | 抗IFN-α/ω抗体の投与方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12202892B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3947448A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022527542A (cg-RX-API-DMAC7.html) |
| MA (1) | MA55559A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020202106A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3117102A1 (en) | 2018-10-26 | 2020-04-30 | Janssen Biotech, Inc. | Type i interferon signatures and methods of use |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0490233A1 (de) * | 1986-03-10 | 1992-06-17 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Monoclonale Antikörper gegen BgIII-Hybridinterferone, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| PT2418220T (pt) | 2003-12-10 | 2017-10-04 | Squibb & Sons Llc | Anticorpos contra interferão alfa e suas utilizações |
| EP1851248B1 (en) | 2005-02-10 | 2016-08-10 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| ES2549903T3 (es) | 2008-05-07 | 2015-11-03 | Argos Therapeutics, Inc. | Anticuerpos humanizados contra interferón alfa humano |
| RU2013157177A (ru) * | 2011-05-25 | 2015-06-27 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения системной красной волчанки, склеродермии и миозита |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
-
2020
- 2020-04-03 US US16/839,249 patent/US12202892B2/en active Active
- 2020-04-03 JP JP2021558985A patent/JP2022527542A/ja active Pending
- 2020-04-03 WO PCT/IB2020/053221 patent/WO2020202106A1/en not_active Ceased
- 2020-04-03 MA MA055559A patent/MA55559A/fr unknown
- 2020-04-03 EP EP20783329.4A patent/EP3947448A4/en active Pending
-
2024
- 2024-09-04 JP JP2024152418A patent/JP2025000638A/ja active Pending
- 2024-12-09 US US18/974,431 patent/US20250376516A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1214043C (zh) | 抗γ-干扰素的人化抗体 | |
| JP2025172841A5 (cg-RX-API-DMAC7.html) | ||
| US8178092B2 (en) | Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23 | |
| JP2023548858A5 (cg-RX-API-DMAC7.html) | ||
| US12565526B2 (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| JP2021533204A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515493A5 (cg-RX-API-DMAC7.html) | ||
| KR20150038227A (ko) | 건선의 치료방법 | |
| US20230049011A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| WO2025223497A1 (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| JP2024511853A5 (cg-RX-API-DMAC7.html) | ||
| JP2022534494A5 (cg-RX-API-DMAC7.html) | ||
| KR20250173550A (ko) | 자가면역 용혈성 빈혈(aiha) 치료를 위한 방법 및 조성물 | |
| JP2022530063A (ja) | 抗体製剤 | |
| JP2025526370A (ja) | 免疫グロブリン様転写物7(ilt7)結合タンパク質を含む製剤 | |
| TW202302147A (zh) | 使用抗baffr抗體治療狼瘡腎炎 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| TW201309329A (zh) | 結合人類il-12之人類抗體及其用途 | |
| CN116685351A (zh) | Empacta的结果:一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 | |
| US20250230238A1 (en) | Methods and compositions for treating systemic lupus erythematous (sle) | |
| JP2022502380A5 (cg-RX-API-DMAC7.html) | ||
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| WO2025188845A1 (en) | STABLE FORMULATIONS FOR TNFα ANTIBODIES AND USES THEREOF |